Goldstein D, O'Leary M, Mitchen J, Borden E C, Wilding G
Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison.
J Urol. 1991 Oct;146(4):1173-7. doi: 10.1016/s0022-5347(17)38034-5.
The effect of interferon beta ser (IFN beta ser) on the growth of three prostatic cancer cell lines DU-145, PC-3 and LNCaP was studied. IFN beta ser inhibited growth of anchorage dependent semiconfluent monolayers and anchorage dependent colony formation of both DU-145 and PC-3 in a dose dependent manner but had no effect on LNCaP. Transforming growth factor beta (TGF beta 1) inhibited proliferation of DU-145 and PC-3 cells in 1% but not 8% fetal calf serum. The combination of TGF beta 1 and IFN beta ser was additive in its effects on growth. Neither epidermal growth factor (EGF) nor transforming growth factor alpha (TGF alpha) reduced the antiproliferative effect of IFN beta ser on these cells. These antiproliferative effects were reproduced in studies on primary epithelial cell cultures derived from prostate specimens with various pathologies. The potential use of IFN beta ser in combination with hormonal therapy to delay the development of hormone refractory tumors is discussed.
研究了β-干扰素(IFNβser)对三种前列腺癌细胞系DU-145、PC-3和LNCaP生长的影响。IFNβser以剂量依赖的方式抑制DU-145和PC-3的贴壁依赖性半汇合单层生长和贴壁依赖性集落形成,但对LNCaP没有影响。转化生长因子β(TGFβ1)在1%胎牛血清中可抑制DU-145和PC-3细胞的增殖,但在8%胎牛血清中则无此作用。TGFβ1和IFNβser联合使用对细胞生长的抑制作用具有相加性。表皮生长因子(EGF)和转化生长因子α(TGFα)均未降低IFNβser对这些细胞的抗增殖作用。在对源自各种病理状态前列腺标本的原代上皮细胞培养物的研究中,也重现了这些抗增殖作用。文中还讨论了IFNβser联合激素疗法延迟激素难治性肿瘤发展的潜在用途。